The Synergistic Effect of 5-Aza-2′-Deoxycytidine and 5-Fluorouracil on Drug-Resistant Tumors
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: We investigated whether a 5-fluorouracil (5-FU)-resistant tumor could regain chemosensitivity after the administration of 5-aza-2′-deoxycytidine (DAC) as a demethylating agent. Methods: Human colorectal cancer cells (SW48) are characterized by the hypermethylation of proapoptotic genes. They were transplanted into 20 athymic BALB/c nu/nu mice which were randomly placed into 4 groups (1 = control; 2 = 5-FU alone; 3 = DAC alone; 4 = DAC followed by 5-FU). We evaluated the synergistic effect of DAC and 5-FU on the growth of these xenografts. Reactivation of proapoptotic genes in these cells was analyzed by methylation-specific PCR. Gene expression was determined by a quantitative reverse-transcription PCR assay. Results: Compared with the control group, relative tumor volumes were statistically significantly decreased only in group 4 mice (p = 0.006). In groups 3 and 4, p14, p16 and death-associated protein kinase (DAPK) promoter regions were demethylated and p14 gene expression was gradually increased after DAC administration. Conclusion: DAC could be a useful medicine that breaks the silencing of various genes and recovers some expressions. By pretreating with DAC at a nontoxic level, we confirmed the restoration of 5-FU chemosensitivity and apoptosis induction. The combination of demethylating agents and several cytotoxic drugs has potential in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, DNMT inhibitors were demonstrated to restore 5-FU sensitivity to 5-FU-resistant CRC cells in mouse xenograft tumor models [162,163].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [162]
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648 · cited 1×
“Therefore, defects in the apoptotic pathway may make cancer cells resistant to 5-FU.Genome mutation and deletion had been thought to be the leading causes of carcinogenesis. However, it has increasingly become clear that epigenetic changes such as DNA methylation and histone acetylation, leading to inactivation of gen…”
Background5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 1×
“5-Aza-2′-deoxycytidine (DAC) has been widely used as a DNA methylation inhibitor [”
MethodChristman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,525
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,408
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
Esteller, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205600 · Cited by 1,233
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
DNA hypomethylation leads to elevated mutation rates
Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L., & Jaenisch, R. (1998) · Nature · doi:10.1038/25779 · Cited by 954 · cited 1×
“Further research into the relationship between DPD and demethylating agents is needed. Methylation seems to be closely related to chemosensitivity. Because multiple genes become methylated in individual cancers, many targets may be affected by a single drug, like DAC, and the chemotherapeutic effect might even be pred…”
BackgroundJones, R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg962 · Cited by 828
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2002) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743
Jüttermann, R., Li, E., & Jaenisch, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.11797 · Cited by 678 · cited 1×
“DAC is incorporated into the DNA of replicating cells in substitution of deoxycytidine to form covalent adducts with the DNA methyltransferase [”
BackgroundWijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Esteller, M., Tórtola, S., Toyota, M., Capellá, G., Peinado, M. A., Baylin, S. B., & Herman, J. G. (2000) · PubMed · Cited by 531
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
A systematic profile of DNA methylation in human cancer cell lines.
Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollán, M., Herman, J. G., & Esteller, M. (2003) · PubMed · Cited by 420
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
Santini, V., Kantarjian, H. M., & Issa, J.-P. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00011 · Cited by 414
Cell-cycle arrest versus cell death in cancer therapy
Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., & Williams, J. (1997) · Nature Medicine · doi:10.1038/nm0997-1034 · Cited by 389 · cited 1×
“Although chemotherapy has been successful in the treatment of some tumors, such as testicular cancer and certain types of leukemia, the outcome of common epithelial tumors like those of the breast, colon and lung has been less than spectacular. Apoptosis might represent the final common step in the cytotoxicity exerte…”
BackgroundDAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
Raveh, T., Droguett, G., Horwitz, M. S., DePinho, R. A., & Kimchi, A. (2001) · Nature Cell Biology · doi:10.1038/35050500 · Cited by 361 · cited 1×
“DAPK had also been shown to be involved in the activation of a p53-dependent apoptotic pathway and to counteract oncogenic action through the activation of p53 in a manner that requires p14 [”
BackgroundDNA methyltransferase inhibitors—state of the art
Goffin, J., & Eisenhauer, E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf314 · Cited by 283
Arnold, C. N., Goel, A., & Boland, C. R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11176 · Cited by 280 · cited 1×
“In addition, 1 report showed that SW48 cells were drug resistant to 5-FU treatment, which is used in the treatment regimens for most colorectal cancers [”
BackgroundConway, K. E., McConnell, B. B., Bowring, C. E., Donald, C. D., Warren, S. T., & Vertino, P. M. (2000) · PubMed · Cited by 249
Etienne, M.-C., Chazal, M., Laurent-Puig, P., Magné, N., Rosty, C., Formento, J.-L., Francoual, M., Formento, P., Renée, N., Chamorey, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.091 · Cited by 176 · cited 1×
“On the other hand, another report showed that DPD, when evaluated according to its enzymatic activity, did not play a major role in predicting the 5-FU responsiveness or survival of patients with colorectal cancer [”
Karpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09243-5 · Cited by 176
Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R. D., & Wang, J. Y. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438031100 · Cited by 168 · cited 1×
“Our data showed no p16 reexpression in the groups treated with DAC. p16 might play an important role in the observed growth inhibition at a higher dose of DAC which was toxic, and the discrepancy between the in vitro and in vivo results might be the actual concentration difference or that the increases in gene express…”
BackgroundAberrant Methylation and Silencing of the BNIP3 Gene in Colorectal and Gastric Cancer
Murai, M., Toyota, M., Suzuki, H., Satoh, A., Sasaki, Y., Akino, K., Ueno, M., Takahashi, F., Kusano, M., Mita, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1021.11.3 · Cited by 154
Methylation and colorectal cancer
Jubb, A. M., Bell, S. M., & Quirke, P. (2001) · The Journal of Pathology · doi:10.1002/path.923 · Cited by 142
Samlowski, W. E., Leachman, S. A., Wade, M., Cassidy, P., Porter-Gill, P., Busby, L., Wheeler, R., Boucher, K., Fitzpatrick, F., Jones, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.118 · Cited by 139
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
Kantarjian, H., O'Brien, S., Keating, M. J., Beran, M., Estey, E. H., Giralt, S. A., Kornblau, S. M., Rios, M., Vos, D. D., & Talpaz, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400796 · Cited by 130
Bartke, T., Siegmund, D., Peters, N., Reichwein, M., Henkler, F., Scheurich, P., & Wajant, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204124 · Cited by 128
Abele, R., Clavel, M., Dodion, P. F., Bruntsch, U., Gundersen, S., Smyth, J., Renard, J., Glabbeke, M. M. V., & Pinedo, H. M. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90060-5 · Cited by 120 · cited 1×
“As a result, DAC reactivates genes that are silenced by aberrant promoter methylation in direct repeats, especially in CpG islands of promoter regions. DAC has been evaluated in clinical trials in patients with solid tumors and hematopoietic disorders [”
BackgroundShen, L., Kondo, Y., Hamilton, S. R., Rashid, A., & Issa, J. J. (2003) · Gastroenterology · doi:10.1053/gast.2003.50102 · Cited by 101
Tillman, D. M., Peták, I., & Houghton, J. A. (1999) · PubMed · Cited by 98
Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P. A., Louwagie, E. A., Berneman, Z. N., T'Jean, M., Wijermans, P., Döhner, H., et al. (1997) · PubMed · Cited by 87
Noguchi, T., Tanimoto, K., Shimokuni, T., Ukon, K., Tsujimoto, H., Fukushima, M., Noguchi, T., Kawahara, K., Hiyama, K., & Nishiyama, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0337 · Cited by 59
Schwartsmann, G., Fernandes, M. S., Schaan, M., Moschen, M., Gerhardt, L. M., Leone, L. D., Loitzembauer, B., & Kalakun, L. (1997) · PubMed · Cited by 55
Adachi, Y., Taketani, S., Oyaizu, H., Ikebukuro, K., Tokunaga, R., & Ikehara, S. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.6.1191 · Cited by 46
Clavel, M., Monfardini, S., Fosså, S. D., Smyth, J., Renard, J., & Kaye, S. B. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058216 · Cited by 28
Cited by
Nucleoside analogs: molecular mechanisms signaling cell death
Ewald, B., Sampath, D., & Plunkett, W. (2008) · Oncogene · doi:10.1038/onc.2008.316 · Cited by 247
“The azanucleosides analogs have also shown synergistic activity with conventional nucleoside analog chemotherapeutic agents such as 5-fluorouracil, which is based on their ability to reactivate previously silenced proapoptotic genes (Kanda et al., 2005; Morita et al., 2006).”
BackgroundChuang, J. C., Warner, S. L., Vollmer, D., Vankayalapati, H., Redkar, S., Bearss, D. J., Qiu, X., Yoo, C. B., & Jones, P. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1048 · Cited by 155
Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?
Tse, J. W. T., Jenkins, L. J., Chionh, F. J. M., & Mariadason, J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.003 · Cited by 148
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 118
Howell, P., Liu, S., Ren, S., Behlen, C., Fodstad, Ø., & Riker, A. I. (2009) · Cancer Control · doi:10.1177/107327480901600302 · Cited by 100
Metadata
- Authors
- Morita, S., Iida, S., Kato, K., Takagi, Y., Uetake, H., & Sugihara, K.
- Affiliations
- Tokyo Medical and Dental University (JP)
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 71
- Issue
- 5-6
- Pages
- 437-445
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2069096225
- Cited by
- 29
- References
- 39
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2013: 3 · 2012: 4
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- decitabine, 5-fluorouracil, drug resistance, colorectal cancer, DNA methylation, hypomethylating agents, gene reactivation, p14, p16, DAPK, apoptosis, drug synergy, xenograft tumor growth
- MeSH terms
- Decitabine, Animals, Azacitidine, Drug Synergism, Fluorouracil, Humans, Mice, Nude, Colorectal Neoplasms, Up-Regulation, Apoptosis, Calcium-Calmodulin-Dependent Protein Kinases, Drug Resistance, Neoplasm, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Tumor Suppressor Protein p14ARF, Cell Line, Tumor, Cell Proliferation, Apoptosis Regulatory Proteins, Mice, Death-Associated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.